You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Addressing Tolerability Concerns Associated With CFTR Modulators

  • Authors: Natalie E. West, MD, MHS; Christopher H. Goss, MD, MSc
  • CME Released: 10/14/2016
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 10/14/2017, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for pulmonologists, pediatricians, and gastroenterologists.

The goal of this activity is to provide clinicians with insight on minimizing and managing reactions to the initiation of lumacaftor/ivacaftor therapy.

Upon completion of this activity, participants will have increased knowledge regarding the:

  1. Adverse events associated with the initiation of cystic fibrosis transmembrane conductance regulator (CFTR) modulators
  2. Strategies to improve provider and patient decision making in the management of adverse events that may occur with the use of CFTR modulators


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Natalie E. West, MD, MHS

    Assistant Professor of Medicine, Assistant Program Director, Pulmonary and Critical Care Fellowship, Johns Hopkins University Pulmonary and Critical Care Medicine, Baltimore, Maryland

    Disclosures

    Participation by Dr. West does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

    Disclosure: Natalie E. West, MD, MHS, has disclosed no relevant financial relationships.

    Dr West does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr West does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Christopher H. Goss, MD, MSc

    Professor of Medicine and Pediatrics, Division of Pulmonary and Critical Care Medicine,  University of Washington, Seattle, Washington

    Disclosures

    Disclosure: Christopher H. Goss, MD, MSc, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.
    Grant reviews for: Gilead Sciences, Inc.; Vertex Pharmaceuticals Incorporated

    Dr Goss does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Goss does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Julia Muino, MA

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Julia Muino, MA, has disclosed no relevant financial relationships.

CME Reviewer

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements


Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Addressing Tolerability Concerns Associated With CFTR Modulators

Authors: Natalie E. West, MD, MHS; Christopher H. Goss, MD, MScFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 10/14/2016

Valid for credit through: 10/14/2017, 11:59 PM EST

processing....

Abbreviations

AE = adverse events
ALT = alanine transaminase
AST = aspartate transaminase
BMI = body mass index
CF = cystic fibrosis
CFQ-R = Cystic Fibrosis Questionnaire-Revised
CFTR = cystic fibrosis transmembrane conductance regulator
FEV1 = forced expiratory volume in 1 second
INR = international normalized ratio
IV = intravenous
ppFEV1 = percentage of predicted forced expiratory volume in 1 second

« Return to: Addressing Tolerability Concerns Associated With CFTR Modulators
  • Print